BrainStorm Cell Therapeutics Inc. (BCLI)

Executive Summary

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company, with U.S. headquarters in New York and R&D operations in Petach Tikva, Israel, developing autologous (patient's-own-cell) therapies for neurodegenerative diseases, most notably amyotrophic lateral sclerosis (ALS). The company has no approved products and has generated no meaningful commercial revenue. It employs about 20 people, was delisted from Nasdaq in July 2025 for failing minimum shareholder-equity requirements, and now trades on the OTCQB Venture Market with a market capitalization of roughly $11 million — a financially distressed micro-cap.

Core Business Model & How They Work

BrainStorm's platform, NurOwn®, involves harvesting a patient's own bone-marrow-derived mesenchymal stem cells, culturing and inducing them to secrete high levels of neurotrophic factors, cryopreserving them, and re-administering them into the patient's cerebrospinal fluid via lumbar puncture. Because the cells are autologous, there is no immune-rejection risk, but the manufacturing process is bespoke per patient — inherently expensive and difficult to scale compared to an off-the-shelf small-molecule or biologic drug. The company currently has no revenue-generating commercial product; historical funding has come from grants (a fully-received $15.9 million California Institute for Regenerative Medicine grant), a limited number of patients treated under Israel's Hospital Exemption pathway (generating about $3.4 million, which did not cover costs), and capital raises.

Business Segments

Single business — cell-therapy R&D. No reporting segments.

Product Portfolio

• NurOwn® for ALS (lead program): a Phase 3 trial completed in 2020 missed its primary endpoint (though showed numerical improvement in some subgroups); a September 2022 BLA submission received an FDA "refusal to file" and was withdrawn in November 2023; the company subsequently secured FDA agreement (April 2024) on a Special Protocol Assessment for a new Phase 3b trial design, with manufacturing alignment reached in June 2024, and recently partnered with Minaris Advanced Therapies (May 2025) alongside existing partner Catalent for Phase 3b manufacturing.
• NurOwn® for Progressive MS (PMS): Phase 2 completed, showing improvement in walking function, cognition, and visual measures; further development under consideration.
• NurOwn® for Alzheimer's disease: an early-stage program under review given the changing regulatory landscape.

Competitive Landscape

The ALS treatment market includes four FDA-approved therapies — riluzole (modest survival extension), Radicava (modest slowing of decline), Relyvrio (withdrawn from the market in 2024 after its confirmatory Phase 3 trial failed), and Qalsody (approved only for the ultra-rare SOD1-ALS subtype). None offers a durable, broadly effective treatment, leaving meaningful unmet need across roughly 30,000 U.S. ALS patients, with per-patient treatment costs for advanced disease estimated at $100,000-$200,000 annually. BrainStorm's autologous cell-therapy approach is scientifically distinct from these small-molecule/antisense competitors, but it must still prove efficacy in a confirmatory trial after one prior Phase 3 miss and one BLA rejection — a high, unresolved bar.

Strategic Strengths & Risks

Strengths: roughly 30 granted patents covering NurOwn® manufacturing plus newer exosome-based technology (allowed in the U.S., Europe, Australia, and Israel through 2039+); FDA-agreed Special Protocol Assessment for the next pivotal trial, which reduces (but does not eliminate) regulatory risk; manufacturing partnerships with established CDMOs (Catalent, Minaris). Risks: explicit going-concern language and a stated need to raise additional capital; July 2025 Nasdaq delisting; a disclosed material weakness in internal controls that the company has not remediated; a July 2025 FDA Citizen Petition requesting review of NurOwn's efficacy data; one failed Phase 3 trial and one rejected BLA already behind the company, meaning the Phase 3b trial is a make-or-break event; inherently high per-patient manufacturing cost structure typical of autologous cell therapies.

Financial Overview

Aggregate market value of shares held by non-affiliates was approximately $10.5 million as of June 30, 2025; current market cap is approximately $11 million. Specific fiscal 2025 net loss and year-end cash figures were not available in the Item 1/1A excerpt reviewed, but the going-concern disclosure and delisting are strong indicators of a company operating with very limited financial runway.

Summary Conclusion

BrainStorm is a high-risk, pre-revenue clinical-stage biotech betting its future on a confirmatory Phase 3b ALS trial after a prior Phase 3 miss and BLA rejection, compounded by going-concern doubt, a Nasdaq delisting, and unresolved internal-control weaknesses. Any moat here is purely intellectual-property and clinical-know-how based, with no commercial, pricing, or scale advantages until (if) a product is approved.